|
n (events)
|
Univariable
|
P-value
|
Multivariable
|
P-value
|
---|
HR (95% CI)
|
HR (95% CI)
|
---|
Entire cohort
|
Agea
|
Continuous
|
258 (79)
|
1.04 (1.01–1.07)
|
0.010
|
0.96 (0.59–1.57)
|
0.875
|
Sexa
|
Female
|
79 (23)
|
1.00
| |
1.00
| |
Male
|
179 (56)
|
1.06 (0.65–1.72)
|
0.827
|
1.03 (1.00–1.06)
|
0.078
|
Gradea
|
Low
|
129 (20)
|
1.00
| |
1.00
| |
High
|
129 (59)
|
3.86 (2.32–6.42)
|
<0.001
|
1.61 (0.82–3.18)
|
0.165
|
Stagea
|
Ta
|
113 (16)
|
1.00
| |
1.00
| |
T1
|
81 (21)
|
2.20 (1.14–4.21)
|
0.018
|
1.69 (0.81–3.56)
|
0.165
|
T2–T4
|
64 (42)
|
8.20 (4.58–14.66)
|
<0.001
|
4.85 (2.23–10.55)
|
<0.001
|
PODXL expression
|
Non-membranous
|
235 (66)
|
1.00
| |
1.00
| |
Membranous
|
27 (16)
|
3.28 (1.89–5.69)
|
<0.001
|
1.49 (0.83–2.68)
|
0.181
|
RBM3 expression
|
High
|
155 (29)
|
1.00
| |
1.00
| |
Low
|
104 (50)
|
3.19 (2.02–5.04)
|
<0.001
|
1.85 (1.11–3.09)
|
0.018
|
T1 disease
|
Agea
|
Continuous
|
81 (21)
|
1.01 (0.96–1.07)
|
0.604
|
1.08 (1.00–1.17)
|
0.066
|
Sexa
|
Female
|
21 (6)
|
1.00
| |
1.00
| |
Male
|
60 (15)
|
1.05 (0.41–2.72)
|
0.914
|
0.93 (0.36–2.42)
|
0.884
|
Gradea
|
Low
|
28 (4)
|
1.00
| |
1.00
| |
High
|
53 (17)
|
2.17 (0.73–6.47)
|
0.163
|
1.63 (0.50–6.84)
|
0.412
|
PODXL expression
|
Non-membranous
|
73 (18)
|
1.00
| |
1.00
| |
Membranous
|
10 (5)
|
2.83 (1.04–7.72)
|
0.042
|
2.60 (0.91–7.39)
|
0.073
|
RBM3 expression
|
High
|
53 (9)
|
1.00
| |
1.00
| |
Low
|
28 (12)
|
2.64 (1.11–6.27)
|
0.028
|
2.63 (1.01–6.84)
|
0.047
|
T2–T4 disease
|
Agea
|
Continuous
|
64 (42)
|
1.00 (0.96–1.04)
|
0.935
|
1.08 (1.00–1.17)
|
0.066
|
Sexa
|
Female
|
18 (12)
|
1.00
| |
1.00
| |
Male
|
46 (30)
|
0.77 (0.39–1.52)
|
0.453
|
0.93 (0.36–2.42)
|
0.884
|
Gradea
|
Low
|
4 (2)
|
1.00
| |
1.00
| |
High
|
60 (40)
|
1.79 (0.43–7.44)
|
0.424
|
1.63 (0.51–5.25)
|
0.412
|
PODXL expression
|
Non-membranous
|
47 (31)
|
1.00
| |
1.00
| |
Membranous
|
17 (11)
|
1.16 (0.54–2.31)
|
0.669
|
1.08 (0.53–2.20)
|
0.832
|
RBM3 expression
|
High
|
18 (9)
|
1.00
| |
1.00
| |
Low
|
46 (33)
|
2.01 (0.95–4.23)
|
0.066
|
2.22 (0.94–5.28)
|
0.071
|
-
aCases included in the univariable analysis of clinicopathological factors were those that had information on both PODXL and RBM3 expression